litlas
Log inCreate account

Stefan Suciu

Active 1986–2024

98
Papers
20,835
Citations
78
h-index
98
i10-index

Citations

Citations per year for Stefan Suciu1948: 2 citations1986: 2 citations1987: 2 citations1988: 2 citations1989: 5 citations1990: 5 citations1991: 8 citations1992: 1 citations1993: 14 citations1994: 11 citations1995: 18 citations1996: 18 citations1997: 35 citations1998: 37 citations1999: 48 citations2000: 81 citations2001: 57 citations2002: 85 citations2003: 101 citations2004: 63 citations2005: 86 citations2006: 91 citations2007: 81 citations2008: 95 citations2009: 120 citations2010: 97 citations2011: 132 citations2012: 105 citations2013: 167 citations2014: 98 citations2015: 128 citations2016: 171 citations2017: 176 citations2018: 214 citations2019: 769 citations2020: 701 citations2021: 723 citations2022: 520 citations2023: 409 citations2024: 540 citations2025: 238 citations2026: 1 citations1949–1985: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,084 citing papers, 24.3% of this breakdownGermany: 672 citing papers, 7.8% of this breakdownItaly: 573 citing papers, 6.7% of this breakdownFrance: 535 citing papers, 6.2% of this breakdownChina: 533 citing papers, 6.2% of this breakdownUnited Kingdom: 522 citing papers, 6.1% of this breakdownNetherlands: 496 citing papers, 5.8% of this breakdownAustralia: 382 citing papers, 4.4% of this breakdownCanada: 242 citing papers, 2.8% of this breakdownSwitzerland: 241 citing papers, 2.8% of this breakdownSpain: 239 citing papers, 2.8% of this breakdownBelgium: 235 citing papers, 2.7% of this breakdown
0%24.3%Other 21.4%

Institutions

Fields

  • Medicine78.1%
  • Biochemistry, Genetics and Molecular Biology11.2%
  • Immunology and Microbiology8.6%
  • Engineering0.5%
  • Neuroscience0.3%
  • Materials Science0.3%
  • Other1%

Topics

  • Cancer Immunotherapy and Biomarkers10.5%
  • Acute Myeloid Leukemia Research6.8%
  • Immunotherapy and Immune Responses6.6%
  • Cutaneous Melanoma Detection and Management5.2%
  • Acute Lymphoblastic Leukemia research5.1%
  • CAR-T cell therapy research4.8%
  • Other61%

Coauthors

All papers

Open in search
  1. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Authors: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert - New England Journal of Medicine 2018 cited by 1,853

  2. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci and 32 more - The Lancet Oncology 2021 cited by 389

  3. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

    Authors: Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Caroline Robert, Stefan Suciu - JAMA Oncology 2020 cited by 436

  4. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Authors: Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Lars Bastholt, Laurent Mortier, L. Thomas, Saad Tahir, Axel Hauschild, Jessica C. Hassel, F. Stephen Hodi, Corina Taitt, Veerle de Pril, Gaetan de Schaetzen, Stefan Suciu, Alessandro Testori - New England Journal of Medicine 2016 cited by 1,313

  5. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

    Authors: Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Paul Lorigan, Dmitri Grebennik, Clemens Krepler, Sandrine Marréaud, Stefan Suciu, Caroline Robert - NEJM Evidence 2022 cited by 150

  6. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Authors: Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Cyril Konto, Axel Hoos, Veerle de Pril, Ravichandra Karra Gurunath, Gaetan de Schaetzen, Stefan Suciu, Alessandro Testori - The Lancet Oncology 2015 cited by 1,255

  7. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

    Authors: Leila Khoja, Eshetu G. Atenafu, Stefan Suciu, Serge Leyvraz, Takami Sato, E. Marshall, Ulrich Keilholz, Lisa Zimmer, Sapna P. Patel, Sophie Piperno‐Neumann, Josep M. Piulats, Tero Kivelä, Claudia Pfoehler, Shailender Bhatia, Peter Huppert, L.B.J. van Iersel, I. Jolanda M. de Vries, Nicolas Penel, Thomas J. Vogl, Tina Cheng, Giammaria Fiorentini, F. Mouriaux, Ahmad A. Tarhini, Poulam M. Patel, Richard D. Carvajal, Anthony M. Joshua - Annals of Oncology 2019 cited by 286

  8. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

    Authors: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert - Journal of Clinical Oncology 2020 cited by 281

  9. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

    Authors: Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Fareeda Hosein, Veerle de Pril, Michal Kiciński, Stefan Suciu, Alessandro Testori - European Journal of Cancer 2019 cited by 180

  10. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

    Authors: Sergio Amadori, Stefan Suciu, Dominik Selleslag, Franco Aversa, Gianluca Gaïdano, Maurizio Musso, Luciana Annino, Adriano Venditti, Maria Teresa Voso, Carla Mazzone, Domenico Magro, Paolo de Fabritiis, Petra Muus, Giuliana Alimena, Marco Mancini, Anne Hagemeijer, Francesca Paoloni, Marco Vignetti, Paola Fazi, Liv Meert, Safaa Ramadan, Roel Willemze, Théo de Witte, Frédéric Baron - Journal of Clinical Oncology 2016 cited by 348

  11. Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

    Authors: Michael Lübbert, Stefan Suciu, Liliana Baila, Björn Rüter, Uwe Platzbecker, Aristoteles Giagounidis, Dominik Selleslag, Boris Labar, Ulrich Germing, Helmut R. Salih, F Beeldens, Petra Muus, Karl-Heinz Pflüger, Corneel Coens, Anne Hagemeijer, Hans E. Schaefer, Arnold Ganser, Carlo Aul, Théo de Witte, Pierre W. Wijermans - Journal of Clinical Oncology 2011 cited by 551

  12. Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

    Authors: Oliver Kennedy, Michal Kiciński, Sara Valpione, Sara Gandini, Stefan Suciu, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandalà - European Journal of Cancer 2022 cited by 49

  13. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

    Authors: Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfonsus JM. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Paul Lorigan, Dmitri Grebennik, Clemens Kreplere, Sandrine Marréaud, Stefan Suciu, Caroline Robert - European Journal of Cancer 2024 cited by 81

  14. Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

    Authors: Fernando Ulloa‐Montoya, Jamila Louahed, Benjamin Dizier, Olivier Gruselle, Bart Spiessens, Frédéric Lehmann, Stefan Suciu, Wim H.J. Kruit, Alexander M.M. Eggermont, Johan Vansteenkiste, Vincent Brichard - Journal of Clinical Oncology 2013 cited by 475

  15. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

    Authors: Michael Lübbert, Pierre W. Wijermans, Michal Kiciński, Sylvain Chantepie, Walter J. F. M. van der Velden, Richard Noppeney, Laimonas Griškevičius, Andreas Neubauer, Martina Crysandt, Radovan Vrḫovac, Mario Luppi, Stephan Fuhrmann, Ernesta Audisio, Anna Candoni, Olivier Legrand, Robin Foà, Gianluca Gaïdano, Daniëlle van Lammeren‐Venema, Eduardus F. M. Posthuma, Mels Hoogendoorn, Anne Giraut, Marian Stevens‐Kroef, Joop H. Jansen, Aniek O. de Graaf, Fabio Efficace, Emanuele Ammatuna, Jean‐Pierre Vilque, Ralph Wäsch, Heiko Becker, Nicole M. A. Blijlevens, Ulrich Dührsen, Frédéric Baron, Stefan Suciu, Sergio Amadori, Adriano Venditti, Gerwin Huls, Jürgen Finke, Nicolaas Petrus Michael Schaap, Andrius Zucenka, Stephan Metzelder, Edgar Jost, Zinaida Perić, Fabio Forghieri, Bernadino Allione, Maurizio Martelli, Anna Paola Iori, Sebastian Wittnebel, Andrea Mengarelli, Annalisa Imovilli, Attilio Olivieri, Bernard José Marie De Prijck, Marjolein W.M. van der Poel, Christian Junghanß, Helmut Rainer Salih, Agostino Tafuri, José Eduardo Guimarães, Maurizio Musso, Paolo De Fabritiis, Patrice Chevallier, Dominik Luc Selleslag, Nicola Cascavilla, Zwi Berneman, Aurélie Jaspers, Eliana Zuffa, Gaëtan Vanstraelen, Giuseppe Visani, Maria Louisa Henriëtte Cuijpers, Ann De Becker, Anna Maria Mianulli, Björn Hackanson, Georgi Georgiev Mihaylov, Giovanni Martinelli, Stefania Paolini, Pier Luigi Zinzani, Martin Henkes, Haifa Kathrin Al-Ali, Paul La Rosée, Anna Chierichini, Laura Cudillo, Giorgina Specchia, Njetočka Gredelj Šimec, Silvana Franca Capalbo, Giuseppina Spinosa, Stefano Molica, Susan Dorothé de Jonge-Peeters - The Lancet Haematology 2023 cited by 37

  16. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, James Larkin, Paul Lorigan, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Thierry Lesimple, Michele Maio, Gerald P. Linette, Laurent Mortier, Inge Marie Svane, Jacob Schachter, Michael P. Brown, Peter Hersey, Catherine Barrow, Ragini R. Kudchadkar, Caroline Dutriaux, Xinni Song, Pietro Quaglino, Paola Queirolo, Friedegund Meier, Daniil Stroyakovskiy, B. Guillot, Pablo L. Ortiz‐Romero, Lars Bastholt, Claus Garbe, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Carmen Loquai, Frank Meiß, Vanna Chiarion‐Sileni, Gil Bar‐Sela, Bernard M. Fitzharris, Philippe Saïag, Jean‐Philippe Arnault, Jan‐Christoph Simon, Rosalie Stephens, Jean‐François Baurain, Célèste Lebbé, P. Combemale, Reinhard Dummer, Axel Hauschild, Phillip Parente, Naoya Yamazaki, Mohammed Milhem, M.‐T. Leccia, L. Geoffrois, Lutz Kretschmer, Elaine Dunwoodie, John Walker, Michal Lotem, Daniel Hendler, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Marcin Dzienis, Geke A.P. Hospers, Marco Siano, Jessica C. Hassel, Philippa Corrie, Maria-Jose Passos, Max Levin, Christoph Höeller, L. Machet, Sigrun Hallmeyer, Ashita Waterston, V. Descamps, Felix Kiecker, Maureen J.B. Aarts, Henrik Schmidt and 34 more - The Lancet Oncology 2021 cited by 72

  17. Sex Is an Independent Prognostic Indicator for Survival and Relapse/Progression-Free Survival in Metastasized Stage III to IV Melanoma: A Pooled Analysis of Five European Organisation for Research and Treatment of Cancer Randomized Controlled Trials

    Authors: Arjen Joosse, Sandra Collette, Stefan Suciu, Tamar Nijsten, Poulam M. Patel, Ulrich Keilholz, Alexander M.M. Eggermont, J.W.W. Coebergh, Esther de Vries - Journal of Clinical Oncology 2013 cited by 191

  18. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

    Authors: Natalie Ives, Stefan Suciu, Alexander M.M. Eggermont, John M. Kirkwood, Paul Lorigan, Svetomir N. Markovic, Claus Garbe, Keith Wheatley, Rosaria Bufalino, David Cameron, Natale Cascinelli, Valerie Doherty, Alexander M.M. Eggermont, Claus Garbe, Martin Gore, Barry W. Hancock, Rebecca A. Harrison, Natalie Ives, John M. Kirkwood, Michael Kressig, Sandra Lee, Paul Lorigan, Rona M. MacKie, Svetomir N. Markovic, Jerry Marsden, Stefan Suciu, Vera J. Suman, Lesley Turner, Keith Wheatley - European Journal of Cancer 2017 cited by 167

  19. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

    Authors: Serge Leyvraz, Sophie Piperno‐Neumann, Stefan Suciu, J.F. Baurain, Marcin Zdzienicki, Alessandro Testori, Ernest Marshall, M. E. Scheulen, Thomas Jouary, Sylvie Négrier, Jan B. Vermorken, Eckhart Kaempgen, Xavier Durando, Dirk Schadendorf, Ravichandra Karra Gurunath, Ulrich Keilholz - Annals of Oncology 2014 cited by 147

  20. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951

    Authors: Emmanuelle Clappier, Nathalie Grardel, Marleen Bâkkus, Jérôme Rapion, Barbara De Moerloose, Philippe Kastner, Aurélie Caye, J Vivent, V. Costa, Alina Ferster, P Lutz, Françoise Mazingue, Frédéric Millot, Dominique Plantaz, Geneviève Plat, Emmanuel Plouvier, Maryline Poirée, Nicolas Sirvent, Anne Uyttebroeck, Karima Yakouben, Stéphane Girard, Nicole Dastugue, Stefan Suciu, Yves Benoît, Y Bertrand, Hélène Cavé, on behalf of the EORTC-CLG - Leukemia 2015 cited by 103

  21. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

    Authors: Alexander M.M. Eggermont, Stefan Suciu, Mario Santinami, Alessandro Testori, Wim H.J. Kruit, Jeremy Marsden, Cornelis J.A. Punt, François Salès, Martin Gore, Rona M. MacKie, Zvonko Kusić, Reinhard Dummer, Axel Hauschild, E. Musat, Alan Spatz, Ulrich Keilholz - The Lancet 2008 cited by 642

  22. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions

    Authors: Emmanuelle Clappier, Auclerc Mf, Jérôme Rapion, Marleen Bâkkus, Aurélie Caye, A. Khemiri, Claudine Giroux, Lucie Hernandez, Emmanuelle Kabongo, Suvi Savola, Thierry Leblanc, Karima Yakouben, Geneviève Plat, V. Costa, A Ferster, Stéphane Girard, Odile Fenneteau, JM Cayuela, F Sigaux, Nicole Dastugue, Stefan Suciu, Yves Benoît, Y Bertrand, Jean Soulier, Hélène Cavé - Leukemia 2013 cited by 152

  23. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

    Authors: Alexander M.M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, Christian U. Blank, Mario Mandalà, Georgina V. Long, Catherine Barrow, Anna Maria Di Giacomo, Rosalie Fisher, Shahneen Sandhu, Ragini R. Kudchadkar, Pablo L. Ortiz‐Romero, Inge Marie Svane, James Larkin, Susana Puig, Peter Hersey, Pietro Quaglino, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, Peter Mohr, Micaela Hernberg, Vanna Chiarion‐Sileni, Matthew Strother, Axel Hauschild, Naoya Yamazaki, Alexander C. J. van Akkooi, Paul Lorigan, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert - European Journal of Cancer 2021 cited by 28

  24. Expression of MAGE genes in primary and metastatic cutaneous melanoma

    Authors: Francis Brasseur, Donata Rimoldi, Danielle Líénard, Bernard Lethé, S Carrel, Flavio Arienti, Ludwig Suter, R Vanwijck, André Bourlond, Yves Humblet, Angelo Vacca, Marina Conese, Thierry Lahaye, Gérard Degiovanni, Rika Deraemaecker, M. Beauduin, Xavier Sastre, E. Salamon, Brigitte Dréno, Elke Jäger, A. Knuth, Christine Chevreau, Stefan Suciu, Jean‐Marie Lachapelle, P Pouillart, Giorgio Parmiani, Ferdy J. Lejeune, Jean‐Charles Cerottini, Thierry Boon, Marie Marchand - International Journal of Cancer 1995 cited by 285